2026-10-11T14:46:39Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995313 2026-10-01T15:11:22Z category_67901 category_67907 portal_1154 item_type_7 month_year_10_2026

Congress presentation: IMS 2026 Effects of elinzanetant on sleep disturbance by baseline Insomnia Severity Index score: results from the OASIS-1 and -2 clinical trials Rossella E. Nappi (2744353) Pauline M. Maki (7246670) James A. Simon (13763258) JoAnn V. Pinkerton (21671538) Nick Panay (9315613) Christian Seitz (2722336) Cecilia Caetano (18563210) Ioanna Gkioni (21842866) Claudio N. Soares (11037515) Menopause Sleep OASIS-1 OASIS-2 OASIS-3 PROMIS Insomnia Severity Index Sleep disturbances <p dir="ltr">In this post hoc analysis of postmenopausal women from OASIS-1–3 data, elinzanetant improved sleep disturbance vs placebo by Week 1 regardless of baseline Insomnia Severity Index severity. These improvements were sustained until study end and were greatest in those with more severe baseline Insomnia Severity Index scores. This supports elinzanetant's potential to rapidly improve moderate-to-severe sleep disturbance in postmenopausal women.</p> 2026-10-01T15:11:22Z Text Presentation 10.71943/bayer.figshare.33995313.v1 https://figshare.com/articles/presentation/Congress_presentation_IMS_2026_Effects_of_elinzanetant_on_sleep_disturbance_by_baseline_Insomnia_Severity_Index_score_results_from_the_OASIS-1_and_-2_clinical_trials/33995313 CC BY-ND